07:00 , Aug 6, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV DEAD box...
07:00 , Aug 26, 2002 |  BC Week In Review  |  Clinical News

P54: Phase IIa

In a U.K. Phase IIa study in 27 steroid dependent patients, of which 16 had ulcerative colitis and 11 had Crohn's disease, P54 did not reduce steroid use compared to placebo. However, in a subgroup...
07:00 , Aug 5, 2002 |  BC Week In Review  |  Company News

Phytopharm, Pfizer deal

The companies amended a 1998 deal to develop PYM's develop P57, an appetite suppressant derived from a plant extract to treat obesity and metabolic syndromes (see BioCentury, Aug. 31, 1998). As amended, PYM said partner...
08:00 , Feb 12, 2001 |  BC Week In Review  |  Clinical News

P54: Began Phase II testing

Phytopharm plc (LSE: PYM), Godmanchester, U.K.   Product: P54   Business: Autoimmune/Inflammation   Therapeutic category: NSAID   Target: Cyclo-oxygenase 2, inducible nitric oxide synthase   Description: Combination of curcumin and the essential oils of Curcuma domestica and C. xanthorrhiza...
08:00 , Feb 12, 2001 |  BioCentury  |  Finance

Ebb & Flow

What a difference a year makes. Anticipation of this week's pending publication of the human genetic code in both Nature and Science generated about as much energy on Wall Street as the California power system....
08:00 , Feb 5, 2001 |  BC Extra  |  Clinical News

Phytopharm starts P54 Phase II

Phytopharm (LSE:PYM) began U.K. double-blind, placebo-controlled Phase II testing of its P54 cyclo-oxygenase 2, inducible nitric oxide synthase, in up to 36 patients with steroid-dependent inflammatory bowel disease (ulcerative colitis and Crohn's disease)....
08:00 , Jan 16, 2001 |  BC Week In Review  |  Clinical News

P54: Phase IIa

In a 15-patient U.K. Phase IIa trial of P54, 3 patients with tertiary adenoma receiving the 4, 6 and 8 capsule doses, respectively, had stable disease radiologically for 3 months and 2 patients had stable...
07:00 , Apr 17, 2000 |  BC Week In Review  |  Company News

Phytopharm, Tumkur Chemicals Ltd. deal

PYM made a 10 percent equity investment in Tumkur, a GMP-compliant manufacturer. Tumkur will manufacture two PYM compounds derived from native Indian plants, P54 and P56. P54 is in a Phase IIa cancer chemoprevention trial...
07:00 , Apr 26, 1999 |  BC Week In Review  |  Clinical News

P54: Phase IIa

PYM's 225-patient study did not show a statistical difference between treatment and placebo groups. Patients receiving P54 had a 17 percent reduction in the WOMAC pain index over two months compared to a 20 percent...
07:00 , Apr 26, 1999 |  BioCentury  |  Finance

Across the Rhein

Bolstering a widely held view that Germany's Neuer Markt is perhaps the only hospitable Euro market for biotechs, Rhein Biotech (NMarkt:RBO) raised '24 million ($25.7 million) in its IPO on the Frankfurt exchange for growth...